Cargando…

IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts

Glioblastoma (GBM) is a devastating cancer with basically no curative treatment. Even with aggressive treatment, the median survival is disappointing 14 months. Surgery remains the key treatment and the postoperative survival is determined by the extent of resection. Unfortunately, the invasive grow...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurbegovic, Sorel, Juhl, Karina, Sørensen, Kasper Kildegaard, Leth, Julie, Willemoe, Gro Linno, Christensen, Anders, Adams, Yvonne, Jensen, Anja Ramstedt, von Buchwald, Christian, Skjøth-Rasmussen, Jane, Ploug, Michael, Jensen, Knud J., Kjaer, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210614/
https://www.ncbi.nlm.nih.gov/pubmed/34158842
http://dx.doi.org/10.7150/thno.49787
_version_ 1783709347979722752
author Kurbegovic, Sorel
Juhl, Karina
Sørensen, Kasper Kildegaard
Leth, Julie
Willemoe, Gro Linno
Christensen, Anders
Adams, Yvonne
Jensen, Anja Ramstedt
von Buchwald, Christian
Skjøth-Rasmussen, Jane
Ploug, Michael
Jensen, Knud J.
Kjaer, Andreas
author_facet Kurbegovic, Sorel
Juhl, Karina
Sørensen, Kasper Kildegaard
Leth, Julie
Willemoe, Gro Linno
Christensen, Anders
Adams, Yvonne
Jensen, Anja Ramstedt
von Buchwald, Christian
Skjøth-Rasmussen, Jane
Ploug, Michael
Jensen, Knud J.
Kjaer, Andreas
author_sort Kurbegovic, Sorel
collection PubMed
description Glioblastoma (GBM) is a devastating cancer with basically no curative treatment. Even with aggressive treatment, the median survival is disappointing 14 months. Surgery remains the key treatment and the postoperative survival is determined by the extent of resection. Unfortunately, the invasive growth with irregular infiltrating margins complicates an optimal surgical resection. Precise intraoperative tumor visualization is therefore highly needed and molecular targeted near-infrared (NIR) fluorescence imaging potentially constitutes such a tool. The urokinase-type Plasminogen Activator Receptor (uPAR) is expressed in most solid cancers primarily at the invading front and the adjacent activated peritumoral stroma making it an attractive target for targeted fluorescence imaging. The purpose of this study was to develop and evaluate a new uPAR-targeted optical probe, IRDye800CW-AE344, for fluorescence guided surgery (FGS). Methods: In the present study we characterized the fluorescent probe with regard to binding affinity, optical properties, and plasma stability. Further, in vivo imaging characterization was performed in nude mice with orthotopic human patient derived glioblastoma xenografts, and we performed head-to-head comparison within FGS between our probe and the traditional procedure using 5-ALA. Finally, the blood-brain barrier (BBB) penetration was characterized in a 3D BBB spheroid model. Results: The probe effectively visualized GBM in vivo with a tumor-to-background ratio (TBR) above 4.5 between 1 to 12 h post injection and could be used for FGS of orthotopic human glioblastoma xenografts in mice where it was superior to 5-ALA. The probe showed a favorable safety profile with no evidence of any acute toxicity. Finally, the 3D BBB model showed uptake of the probe into the spheroids indicating that the probe crosses the BBB. Conclusion: IRDye800CW-AE344 is a promising uPAR-targeted optical probe for FGS and a candidate for translation into human use.
format Online
Article
Text
id pubmed-8210614
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-82106142021-06-21 IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts Kurbegovic, Sorel Juhl, Karina Sørensen, Kasper Kildegaard Leth, Julie Willemoe, Gro Linno Christensen, Anders Adams, Yvonne Jensen, Anja Ramstedt von Buchwald, Christian Skjøth-Rasmussen, Jane Ploug, Michael Jensen, Knud J. Kjaer, Andreas Theranostics Research Paper Glioblastoma (GBM) is a devastating cancer with basically no curative treatment. Even with aggressive treatment, the median survival is disappointing 14 months. Surgery remains the key treatment and the postoperative survival is determined by the extent of resection. Unfortunately, the invasive growth with irregular infiltrating margins complicates an optimal surgical resection. Precise intraoperative tumor visualization is therefore highly needed and molecular targeted near-infrared (NIR) fluorescence imaging potentially constitutes such a tool. The urokinase-type Plasminogen Activator Receptor (uPAR) is expressed in most solid cancers primarily at the invading front and the adjacent activated peritumoral stroma making it an attractive target for targeted fluorescence imaging. The purpose of this study was to develop and evaluate a new uPAR-targeted optical probe, IRDye800CW-AE344, for fluorescence guided surgery (FGS). Methods: In the present study we characterized the fluorescent probe with regard to binding affinity, optical properties, and plasma stability. Further, in vivo imaging characterization was performed in nude mice with orthotopic human patient derived glioblastoma xenografts, and we performed head-to-head comparison within FGS between our probe and the traditional procedure using 5-ALA. Finally, the blood-brain barrier (BBB) penetration was characterized in a 3D BBB spheroid model. Results: The probe effectively visualized GBM in vivo with a tumor-to-background ratio (TBR) above 4.5 between 1 to 12 h post injection and could be used for FGS of orthotopic human glioblastoma xenografts in mice where it was superior to 5-ALA. The probe showed a favorable safety profile with no evidence of any acute toxicity. Finally, the 3D BBB model showed uptake of the probe into the spheroids indicating that the probe crosses the BBB. Conclusion: IRDye800CW-AE344 is a promising uPAR-targeted optical probe for FGS and a candidate for translation into human use. Ivyspring International Publisher 2021-05-21 /pmc/articles/PMC8210614/ /pubmed/34158842 http://dx.doi.org/10.7150/thno.49787 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Kurbegovic, Sorel
Juhl, Karina
Sørensen, Kasper Kildegaard
Leth, Julie
Willemoe, Gro Linno
Christensen, Anders
Adams, Yvonne
Jensen, Anja Ramstedt
von Buchwald, Christian
Skjøth-Rasmussen, Jane
Ploug, Michael
Jensen, Knud J.
Kjaer, Andreas
IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts
title IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts
title_full IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts
title_fullStr IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts
title_full_unstemmed IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts
title_short IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts
title_sort irdye800cw labeled upar-targeting peptide for fluorescence-guided glioblastoma surgery: preclinical studies in orthotopic xenografts
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210614/
https://www.ncbi.nlm.nih.gov/pubmed/34158842
http://dx.doi.org/10.7150/thno.49787
work_keys_str_mv AT kurbegovicsorel irdye800cwlabeledupartargetingpeptideforfluorescenceguidedglioblastomasurgerypreclinicalstudiesinorthotopicxenografts
AT juhlkarina irdye800cwlabeledupartargetingpeptideforfluorescenceguidedglioblastomasurgerypreclinicalstudiesinorthotopicxenografts
AT sørensenkasperkildegaard irdye800cwlabeledupartargetingpeptideforfluorescenceguidedglioblastomasurgerypreclinicalstudiesinorthotopicxenografts
AT lethjulie irdye800cwlabeledupartargetingpeptideforfluorescenceguidedglioblastomasurgerypreclinicalstudiesinorthotopicxenografts
AT willemoegrolinno irdye800cwlabeledupartargetingpeptideforfluorescenceguidedglioblastomasurgerypreclinicalstudiesinorthotopicxenografts
AT christensenanders irdye800cwlabeledupartargetingpeptideforfluorescenceguidedglioblastomasurgerypreclinicalstudiesinorthotopicxenografts
AT adamsyvonne irdye800cwlabeledupartargetingpeptideforfluorescenceguidedglioblastomasurgerypreclinicalstudiesinorthotopicxenografts
AT jensenanjaramstedt irdye800cwlabeledupartargetingpeptideforfluorescenceguidedglioblastomasurgerypreclinicalstudiesinorthotopicxenografts
AT vonbuchwaldchristian irdye800cwlabeledupartargetingpeptideforfluorescenceguidedglioblastomasurgerypreclinicalstudiesinorthotopicxenografts
AT skjøthrasmussenjane irdye800cwlabeledupartargetingpeptideforfluorescenceguidedglioblastomasurgerypreclinicalstudiesinorthotopicxenografts
AT plougmichael irdye800cwlabeledupartargetingpeptideforfluorescenceguidedglioblastomasurgerypreclinicalstudiesinorthotopicxenografts
AT jensenknudj irdye800cwlabeledupartargetingpeptideforfluorescenceguidedglioblastomasurgerypreclinicalstudiesinorthotopicxenografts
AT kjaerandreas irdye800cwlabeledupartargetingpeptideforfluorescenceguidedglioblastomasurgerypreclinicalstudiesinorthotopicxenografts